Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Patricia Santofimia‐Castaño

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2506-5567; OpenAlex author ID A5018793588. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Evaluating the therapeutic role of salvianolic acid A on pancreatic cancer cells through interaction with the intrinsically disordered protein NUPR1. Co-author DOI 10.1016/j.ijbiomac.2025.149435↗
  2. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.tranon.2025.102421↗
  3. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Co-author DOI 10.1073/pnas.2424051122↗
  4. Stroma-targeting strategies in pancreatic cancer: a double-edged sword. Last author DOI 10.1007/s13105-022-00941-1↗
  5. [The mRNA vaccine for the treatment of pancreatic cancer is here to stay]. Co-author PMID 37582144↗
  6. Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells. Co-author DOI 10.1021/jacs.2c03973↗
  7. Combating pancreatic cancer chemoresistance by triggering multiple cell death pathways. Co-author DOI 10.1016/j.pan.2021.01.010↗
  8. Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer. Last author DOI 10.3390/ijms22094970↗
  9. Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. Co-author DOI 10.1158/1078-0432.ccr-20-1232↗
  10. Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers11121869↗
  11. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cells8111453↗
  12. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based t… Co-author DOI 10.1038/s41598-018-26613-z↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 12 shared papers, 2018–2026 · strength 2.26
  2. Nelson Dusetti · 5 shared papers, 2018–2025 · strength 0.72
  3. Nicolas Alejandro Fraunhoffer · 4 shared papers, 2019–2025 · strength 0.61
  4. Matías Estarás · 2 shared papers, 2025–2026 · strength 0.58
  5. Eduardo Chuluyán · 3 shared papers, 2020–2025 · strength 0.49
  6. Analía Meilerman Abuelafia · 3 shared papers, 2019–2025 · strength 0.47
  7. José L. Neira · 2 shared papers, 2019–2026 · strength 0.42
  8. Daniel Grasso · 2 shared papers, 2023–2025 · strength 0.39
  9. Can Huang · 2 shared papers, 2019–2021 · strength 0.34
  10. María Gabriela Álvarez-Rodríguez · 1 shared paper, 2026 · strength 0.33
  11. Raul A. Urrutia · 2 shared papers, 2019–2025 · strength 0.33
  12. Gwen Alyce Lomberk · 2 shared papers, 2019–2025 · strength 0.33
  13. Xi Liu · 1 shared paper, 2023 · strength 0.31
  14. Wenjun Lan · 3 shared papers, 2018–2019 · strength 0.28
  15. Noemí Manero‐Rupérez · 1 shared paper, 2025 · strength 0.20
  16. Renzo Emanuel Vera · 1 shared paper, 2025 · strength 0.20
  17. Judith Vinaixa · 1 shared paper, 2025 · strength 0.20
  18. Neus Martínez‐Bosch · 1 shared paper, 2025 · strength 0.20
  19. David R Pease · 1 shared paper, 2025 · strength 0.20
  20. Pilar Navarro · 1 shared paper, 2025 · strength 0.20
  21. Martín E. Fernández-Zapico · 1 shared paper, 2025 · strength 0.20
  22. Odile Gayet · 2 shared papers, 2018–2020 · strength 0.18
  23. Yi Xia · 2 shared papers, 2018–2019 · strength 0.16
  24. Ling Peng · 2 shared papers, 2018–2019 · strength 0.16
  25. Raphaël Rodriguez · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.